IssuerAnnouncementDetailsV2Portlet
Actions
Al-Razi Medical Co. Announces the Results of the Extraordinary General Assembly Meeting, ( First Meeting )
| Element List | Explanation |
|---|---|
| Introduction | The Board of Directors of Al Razi Medical Company is pleased to announce the results of the first extraordinary general assembly meeting (the first meeting), which was held at 06:30 pm on Sunday 12/17/1445 AH, corresponding to 06/23/2024 AD, at the company’s headquarters in Albadaya Governorate in the region. Al-Qassim using modern technology. |
| City and Location of the General Assembly's Meeting | The company's headquarters is in Albadaya Governorate in the Qassim region using modern technological means. |
| Date of the General Assembly's Meeting | 2024-06-23 Corresponding to 1445-12-17 |
| Time of the General Assembly’s Meeting | 18:30 |
| Percentage of Attending Shareholders | % 77.53 |
| Names of the Board of Directors' Members Present at the General Assembly's Meeting and Names of the Absentees | Attendees: Dr. Youssef bin Abdullah Youssef Alorini - Chairman of the Board of Directors. Abdullah bin Nasser bin Ibrahim Al-Dajan - Vice Chairman of the Board of Directors. Mohammed bin Abdullah bin Mohammed Al-Mousa - Member of the Board of Directors. Abdul Rahman bin Mohammed bin Abdullah Al Suhaibani - Member of the Board of Directors. Abdulaziz bin Abdullah bin Muhammad Al-Awd - Member of the Board of Directors. |
| Names of the Chairmen of the Committees Present at the General Assembly's Meeting or Members of such Committees Attending on Their Behalf | Abdulaziz bin Abdullah bin Muhammad Al-Awd - Chairman of the Audit Committee. Mohammed bin Abdullah bin Mohammed Al-Mousa - Chairman of the Remuneration and Nominations Committee. |
| Voting Results on the Items of the General Assembly's Meeting Agenda's | 1. The Board of Directors’ report for the financial year ending on December 31, 2023 was reviewed and discussed. 2. The financial statements for the fiscal year ending on December 31, 2023 were reviewed and discussed. 3. Approval of the auditor’s report for the fiscal year ending on December 31, 2023 AD after discussion. 4. Approval of the appointment of Ibrahim Ahmed Al-Bassam & Partners Company as the company’s auditor from among the candidates based on the recommendation of the Audit Committee; This is to examine, review and audit the semi-annual and annual financial statements for the fiscal year 2024 AD, for a fee of 175,000 Saudi riyals, excluding value-added tax. 5. Approval to discharge the members of the Board of Directors from their liabilities for the fiscal year ending on December 31, 2023 AD. 6. Approval of the works and contracts concluded between the company and Azod Industrial Company, which the Chairman of the Board of Directors, Dr. Youssef bin Abdullah Al-Arini has an indirect interest in it, which is acting expenses for the year 2023 AD, and there are no preferential conditions, in the amount of (31,817) riyals. 7. Approval of the works and contracts concluded between the company and Azod Industrial Company, which the Chairman of the Board of Directors, Dr. Youssef bin Abdullah Al-Arini has an indirect interest in it, which consists of payments for the year 2023 AD, and there are no preferential conditions, in the amount of (7,581) riyals. 8. Approval of the work and contracts concluded between the company and Azod Industrial Company, which the Chairman of the Board of Directors, Dr. Youssef bin Abdullah Al-Arini has an indirect interest in it, which is leasing the headquarters of the Bentem Pharmaceuticals warehouse and the headquarters of Al-Razi administration for the year 2023 AD, and there are no preferential conditions, for the amount of (23,000) riyals. 9. Approval of the works and contracts concluded between the company and Azod Industrial Company, which the Chairman of the Board of Directors/Dr. Yousef bin Abdullah Al-Arini has an indirect interest in it, which is the transfer of ownership of a fixed asset (a 2015 Nissan Sunny car) from Al-Razi Company to Azod Company during the year 2023 AD, without any preferential conditions, in the amount of (25,000) riyals. 10. Approval of the works and contracts concluded between the company and Azod Industrial Company, which the Chairman of the Board of Directors, Dr. Youssef bin Abdullah Al-Arini has an indirect interest in it, which is commercial transactions as a supplier of medical scales during 2023 AD, and there are no preferential conditions, in the amount of (11,871) riyals. 11. Approval of the works and contracts concluded between the company and Azod Industrial Company, which the Chairman of the Board of Directors/Dr. Youssef bin Abdullah Al-Arini has an indirect interest in it, which consists of electricity, maintenance, guarding, water, and employee housing expenses charged to Azod Industrial Company during the year 2023 AD, and there are no preferential conditions, in the amount of (161,939) riyals. 12. Approval of the work and contracts concluded between the company and the Chairman of the Board of Directors/Dr. Youssef bin Abdullah Al-Arini, in which she has a direct interest, and which are withdrawals during the year 2023 AD, and there are no preferential conditions, in the amount of (21,300) riyals. 13. Approval of the work and contracts concluded between the company and the Chairman of the Board of Directors/Dr. Youssef bin Abdullah Al-Arini, in which it has a direct interest, is sales during the year 2023 AD, and there are no preferential terms, in the amount of (20,420) riyals. 14. Approval of the work and contracts concluded between the company and the Chairman of the Board of Directors/Dr. Youssef bin Abdullah Al-Arini, in which it has a direct interest, which are deposits during 2023 AD, and there are no preferential conditions, in the amount of (41,720) riyals. 15. Approval of amending Article Four of the company’s bylaws, related to the company’s purposes. |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.
Share
Company Performance
Key Parameters
Last Price 42.96
Net Change 0.14 (+0.33%)
Value Traded (Sar) 332,675.6
Volume Traded 7,767
LoginPortletPopupv2
Actions
AddtoWatchlistv2
Actions